Elite in Acute Lymphoblastic Leukemia (ALL)

Pere Barba

Barcelona, CT, ES 
Elite in Acute Lymphoblastic Leukemia (ALL)
Barcelona, CT, ES 
OverviewLocationsClinical Research

Overview

Pere Barba practices in Barcelona, Spain. Barba is rated as an Elite expert by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Their top areas of expertise are Acute Lymphoblastic Leukemia (ALL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Graft.

Their clinical research consists of co-authoring 148 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 38 articles and participated in 1 clinical trial in the study of Acute Lymphoblastic Leukemia (ALL).

Locations

Barcelona, CT, Spain
Other Locations
Bellaterra, CT, Spain
Spain
Madrid, MD 28040, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Study Phase: Phase 3
A Prospective Multicenter Open-label, Not Controlled Phase Ib-II Clinical Trial to Assess the Safety and Immunologic Efficacy of Virus-specific T Lymphocytes From the Best Donor in Receptors of Hematopoietic Progenitor Allogeneic Transplant
A Prospective Multicenter Open-label, Not Controlled Phase Ib-II Clinical Trial to Assess the Safety and Immunologic Efficacy of Virus-specific T Lymphocytes From the Best Donor in Receptors of Hematopoietic Progenitor Allogeneic Transplant
Enrollment Status: Completed
Publish Date: January 24, 2024
Intervention Type: Drug
Study Drug: Activated T-lymphocytes
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

148 Total Publications

Use of Dasatinib for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome After Axicabtagene Ciloleucel Infusion: A Case Report.
Use of Dasatinib for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome After Axicabtagene Ciloleucel Infusion: A Case Report.
Journal: European journal of haematology
Published: July 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Barba's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 14 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile